Deschatelets Pascal 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 22, 2025
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-05-21$3.76/sh+12,780$48,053→ 1,160,496 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-05-21−12,780→ 0 totalExercise: $3.76Exp: 2026-02-06→ Common Stock (12,780 underlying)
Footnotes (1)
- [F1]This stock option was granted on 02/08/2016 and is fully vested.